丁酸盐
结肠炎
免疫学
癌症研究
重编程
溃疡性结肠炎
免疫系统
生物
封锁
肠道菌群
发病机制
丁酸钠
细胞生物学
炎症性肠病
转录组
FOXP3型
微生物学
表观遗传学
下调和上调
平衡
化学
肠上皮
免疫耐受
移植
免疫
巨噬细胞
组蛋白
炎症
肠细胞
巨噬细胞极化
失调
作者
Dengke Yao,Xiaojian Zhu,Jianyong Xiong,Hongtao Wan,Zhijiang Huang,Min Peng,Xujie Deng,Yu He,Jiangfeng Yin,Xianwu Zhang,Yanglin Chen,Xiaoyuan Yang,Rongfeng Song,Dan Liu,Bo Yi
标识
DOI:10.1038/s41522-026-01185-3
摘要
Ulcerative colitis (UC) pathogenesis involves complex interactions between epithelial barrier dysfunction and immune dysregulation. While Astragalus polysaccharide (APS) exhibits anti-inflammatory properties, its mechanistic link to gut microbiota remodeling remains elusive. Using an integrative multi-omics strategy, we demonstrate that APS mitigates dextran sulfate sodium (DSS)-induced colitis by selectively recovering butyrate-producing commensal bacteria, including Ruminococcaceae, Alistipes , Rikenella , and Mucispirillum , thereby increasing fecal butyrate concentrations. Fecal microbiota transplantation (FMT) from APS-treated mice conferred protection against colitis, whereas butyrate supplementation phenocopied the effects of APS. Mechanistically, butyrate inhibited HDAC9 activity, augmenting H3K27ac at the Pparg locus to drive PPARG-ADIPOQ signaling. This epigenetic reprogramming polarized macrophages toward an M2 phenotype, dampened IL-1β/TNF-α production, and restored occludin/claudin-5 expression. Functional recovery experiments further confirmed the necessity of the axis: HDAC9 overexpression or PPARγ/ADIPOQ blockade abolished the therapeutic efficacy of APS. Clinically, human UC biopsy specimens displayed inverse expression patterns between HDAC9 and PPARγ/ADIPOQ, validating the clinical and translational relevance of this epigenetic-metabolic regulatory pathway. Collectively, this study delineates a diet-microbiota-epigenetic interplay wherein microbiota-derived butyrate emerges as a key mediator of APS-induced intestinal mucosal homeostasis through HDAC9/PPARG/ADIPOQ-dependent immunometabolic reprogramming. These results highlight microbiota-driven HDAC inhibition as a promising therapeutic strategy for UC management.
科研通智能强力驱动
Strongly Powered by AbleSci AI